Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands; Division of Infectious Diseases, Amsterdam Infection & Immunity Institute Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Eur J Intern Med. 2021 Dec;94:6-14. doi: 10.1016/j.ejim.2021.08.023. Epub 2021 Sep 23.
Hepatocellular carcinoma (HCC) and variceal bleeding are among the most common causes of liver-related mortality in patients with hepatitis C virus (HCV)-induced cirrhosis. Current guidelines recommend HCC and gastroesophageal varices (GEV) surveillance in patients with HCV infection and cirrhosis. However, since the recent introduction of direct-acting antivirals, most patients with cirrhosis are now cured of their chronic HCV infection. As virological cure is considered to substantially reduce the risk of cirrhosis-related complications, this review discusses the current literature concerning the surveillance of HCC and GEV in patients with HCV-induced cirrhosis with a focus on the setting following sustained virological response.
肝细胞癌（HCC）和静脉曲张出血是丙型肝炎病毒（HCV）引起的肝硬化患者肝相关死亡的最常见原因之一。目前的指南建议对 HCV 感染和肝硬化患者进行 HCC 和胃食管静脉曲张（GEV）监测。然而，由于直接作用抗病毒药物的近期推出，大多数肝硬化患者现在已经治愈了他们的慢性 HCV 感染。由于病毒学治愈被认为可大大降低肝硬化相关并发症的风险，因此，本综述讨论了目前关于 HCV 诱导的肝硬化患者 HCC 和 GEV 监测的文献，重点是持续病毒学应答后的情况。
